Serpin B-6 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Serpin B6 (UniProt P35237), expressed in HEK293 cells. Full 376-aa cytoplasmic serine proteinase inhibitor for activity assays, inhibitor screening, and antibody validation.
Expression system
HEK293
Cat. #
REC-SerpinB6

In stock

SKU
REC-SerpinB6
$498.00

Target Overview

Serpin B6 (UniProt P35237; gene SERPINB6) is a 376-amino-acid intracellular member of the clade B serpin superfamily. Unlike secreted serpins, Serpin B6 is localised to the cytoplasm, where it functions as a stoichiometric inhibitor of serine proteinases — including cathepsin G, kallikrein-8, and thrombin — that may gain access to the cytosol through lysosomal leakage or transient plasma-membrane disruption. This recombinant form is produced in HEK293 cells, providing human-relevant post-translational processing in a well-characterised mammalian expression background. The full-length 376-residue sequence is expressed, yielding a protein suitable for direct use in enzyme–inhibitor kinetic assays, IC50 determinations with proteinase substrates, and co-immunoprecipitation studies examining serpin–proteinase complex formation. Because Serpin B6 is strictly cytoplasmic and lacks a signal peptide, HEK293 expression preserves its native folding characteristics better than most prokaryotic systems — an important consideration when the reactive-centre loop (RCL) conformation governs inhibitory specificity. Researchers use this recombinant to benchmark proteinase inhibition constants (k_ass, k_inh), to identify candidate substrate proteinases by activity-based profiling, and as a well-defined positive control for Western blot and immunohistochemistry validation of anti-Serpin B6 antibodies. For antibody validation workflows, this recombinant pairs directly with the matched Triple Point Biologics anti-Serpin B6 antibody (SKU: RP-SerpinB6), available on the product page linked on this site. Validated human reactivity; mouse, rat, and several additional species are predicted cross-reactive based on sequence homology.

Background

Serpin B6 belongs to the B-clade (ov-serpin) branch of the serpin superfamily, a structurally conserved group of proteinase inhibitors that act via a suicide-substrate mechanism. Upon engagement with a target proteinase, the reactive-centre loop (RCL) is cleaved and undergoes a large-scale conformational change that covalently traps the enzyme in an inactive acyl–enzyme intermediate. Serpin B6's cytoplasmic localisation distinguishes it from plasma serpins such as alpha-1 antitrypsin; its function is thought to be cytoprotective, guarding the cytosol against proteinases that leak from lysosomes during cellular stress. The inner ear has emerged as a particularly important site of Serpin B6 biology. Loss-of-function variants in SERPINB6 are linked to autosomal-recessive nonsyndromic hearing loss (DFNB91), and the protein is hypothesised to protect cochlear hair cells from lysosomal proteinase-mediated apoptosis when cellular homeostasis is perturbed. A 2026 study by Cheng et al. (PMID 41612696) demonstrated that disruption of the Serpinb6a–Gch1 axis in a mouse model reproduces DFNB91 deafness and that this phenotype is amendable to gene-based interventions, establishing the pathway as an active area of mechanistic research. Beyond the auditory system, SERPINB6 has been studied as a transcriptional marker in cancer biology. Wang et al. (2025, PMID 40665565) reported that elevated SERPINB6 expression promotes epithelial-mesenchymal transition (EMT) in glioma via the PI3K/AKT/mTOR signalling axis, positioning the protein as a research target for understanding tumour invasion mechanisms. SERPINB6 transcript levels have also been detected as differentially expressed in microarray analyses of human abdominal aortic aneurysm tissue (Lu et al., 2026, PMID 42049434), and the gene locus has appeared in transcriptomic Mendelian randomisation studies of immune-cell phenotypes in type 1 diabetes (Sklar et al., 2025, PMID 41299435), reflecting broad interest in how cytoplasmic serpin expression varies across disease states. For in-vitro research, this recombinant enables direct measurement of inhibition constants against cathepsin G, kallikrein-8, and thrombin; assessment of RCL-cleavage by SDS-PAGE band-shift assay; and use as a defined antigen in antibody validation and immunoassay development. Triple Point Biologics has been producing proteinase and inhibitor antibody reagents since 1994, and this recombinant is manufactured to complement that antibody portfolio.

Applications

  • Enzyme-inhibitor kinetic assay: determination of association rate constant (k_ass) for cathepsin G, kallikrein-8, or thrombin inhibition
  • SDS-PAGE band-shift (RCL-cleavage) assay to confirm stoichiometric serpin–proteinase complex formation
  • IC50 determination for small-molecule modulators of Serpin B6 inhibitory activity in fluorogenic substrate assays
  • Antibody validation positive control for Western blot using matched anti-Serpin B6 antibody (SKU: RP-SerpinB6)
  • IHC/IF antigen standard for benchmarking anti-Serpin B6 staining intensity and specificity
  • Co-immunoprecipitation or pull-down substrate to identify novel cytoplasmic proteinase binding partners
  • Lysosomal leakage protection model: addition to cell-free cytosol fractions to assess proteinase neutralisation under simulated stress conditions
  • ELISA capture/detection standard for quantification of endogenous Serpin B6 in cell lysate samples

References

  1. Lu S et al. Microarray Analysis of Human Abdominal Aortic Aneurysm With Emphasis on Cardiovascular Genes Revealed Differentially Expressed Genes. In Vivo. 2026. doi:10.21873/invivo.14286. PMID: 42049434.
  2. Cheng C et al. Dysregulation of Serpinb6a-Gch1 axis contributes to DFNB91 deafness that is amendable to gene therapies. Mol Ther. 2026. doi:10.1016/j.ymthe.2026.01.030. PMID: 41612696.
  3. Sklar J et al. Immune cell-based transcriptomic Mendelian randomization and colocalization study on type 1 diabetes. BMC Med. 2025. doi:10.1186/s12916-025-04527-8. PMID: 41299435.
  4. Zacharski M et al. Transcriptional analysis reveals a markedly reduced expression of the voltage-dependent calcium channel α2δ1 subunit in canine prostate cancer compared to benign prostatic hyperplasia. BMC Vet Res. 2025. doi:10.1186/s12917-025-05046-7. PMID: 41068906.
  5. Wang D et al. SERPINB6 Promotes Epithelial-Mesenchymal Transition via PI3K/AKT/mTOR Signalling Pathway in Glioma. J Cell Mol Med. 2025. doi:10.1111/jcmm.70711. PMID: 40665565.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What is the expected molecular weight of recombinant Serpin B-6 on SDS-PAGE and Western blot?

The full-length 376-amino-acid sequence of Serpin B-6 (UniProt P35237) has a calculated molecular weight of approximately 42.6 kDa. On reducing SDS-PAGE, this HEK293-expressed recombinant typically resolves as a single band at ~44–46 kDa — the slight upward shift relative to theoretical MW is consistent with mammalian post-translational modifications. Purity is >90% by SDS-PAGE. When running Western blot positive controls alongside RP-SerpinB6 antibody validation, load this band as your reference at the 44–46 kDa position.

Does recombinant Serpin B-6 undergo any proteolytic processing or isoform variation I should account for?

Serpin B-6 is expressed as the canonical full-length 376-residue sequence without a signal peptide, consistent with its strictly cytoplasmic localisation. No known signal-peptide cleavage or pro-domain processing is expected. However, serpins can form a cleaved, relaxed conformation after stoichiometric proteinase engagement — so if your recombinant has been exposed to a target proteinase (e.g., during activity testing), you may observe a secondary band ~2–4 kDa lower on reducing SDS-PAGE, representing the cleaved inhibitory form. Fresh, proteinase-naive aliquots should show a single band.

Which proteinases does Serpin B-6 inhibit, and can I use it directly in an enzyme inhibition kinetic assay?

Serpin B-6 functions as a stoichiometric inhibitor of serine proteinases including cathepsin G, kallikrein-8, and thrombin that may access the cytosol through lysosomal leakage or membrane disruption. This recombinant is produced in active inhibitory form and is suitable for direct use in enzyme–inhibitor kinetic assays and IC50 determinations. Pair it with fluorogenic substrates appropriate to your target proteinase — for example, Suc-AAPF-AMC for cathepsin G, or tosyl-GPR-AMC for thrombin — monitoring substrate cleavage inhibition at 380/460 nm excitation/emission.

What buffer and assay conditions should I use for a Serpin B-6 inhibition kinetic assay?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — a buffer compatible with most serine proteinase activity assays without dilution-induced pH shifts. For kinetic experiments, dilute to working concentration in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01% Tween-20 or 0.1% BSA to prevent adsorption at low protein concentrations. Avoid calcium-free buffers if your target proteinase requires divalent cations. Glycerol at 10% should be tolerated by most fluorometric plate readers, but validate background fluorescence from carrier buffer using a no-protein control.

What starting concentration of recombinant Serpin B-6 should I use for IC50 determination against cathepsin G?

Because Serpin B-6 acts stoichiometrically rather than catalytically, IC50 experiments require molar-ratio titrations rather than classical Michaelis-Menten approaches. A practical starting point is a Serpin B-6 concentration range of 10–500 nM against a fixed cathepsin G concentration of 10–50 nM, with substrate (e.g., Suc-AAPF-AMC) at or below Km (~100 µM). Pre-incubate inhibitor and proteinase for 30 minutes at 37°C before adding substrate to allow complex formation. Adjust based on your enzyme lot's specific activity. The stoichiometry of inhibition (SI) should be characterised alongside apparent Ki for full kinetic characterisation.

Can I use Serpin B-6 (Recombinant) as a positive control for Western blot with the RP-SerpinB6 antibody?

Yes — this recombinant is the recommended positive control for RP-SerpinB6 (/anti-serpin-b6-rabbit-polyclonal-antibody). The antibody and recombinant are produced from the same lab pipeline, ensuring epitope compatibility is validated rather than assumed. Load 20–50 ng of recombinant per lane alongside your cell lysate samples. Under standard reducing conditions, expect a clean band at ~44–46 kDa. This pairing is particularly useful when validating RP-SerpinB6 in new cell or tissue lysate backgrounds where endogenous Serpin B-6 expression is uncertain or low.

How much recombinant Serpin B-6 should I load per lane for Western blot to avoid signal saturation with RP-SerpinB6?

For a standard ECL detection setup with RP-SerpinB6 at 1:1000 dilution, loading 20–50 ng of recombinant Serpin B-6 per lane typically yields a strong, non-saturated signal. If you are using high-sensitivity chemiluminescence substrates or HRP-conjugates with amplification, start at 5–10 ng to avoid blooming that obscures the band boundary. Run a two- to three-point titration (10, 25, 50 ng) alongside your lysate lanes on the first use to calibrate signal linearity and confirm the 44–46 kDa band position before committing to a fixed loading amount.

How should I store and handle recombinant Serpin B-6 to maintain inhibitory activity over time?

Store at -20°C in single-use aliquots as supplied. Repeated freeze-thaw cycles progressively denature serpins and can drive loop-sheet polymerisation, abolishing inhibitory activity without obvious change in SDS-PAGE band appearance. Upon first use, thaw on ice, briefly centrifuge (2,000 × g, 1 min) to collect any condensate, and dilute immediately into assay buffer. Do not leave protein at room temperature for more than 30 minutes before use. Working dilutions in BSA-supplemented buffer can be held at 4°C for up to 24 hours, but prepare fresh aliquots for each independent experiment for reproducible kinetic data.

Validation imagery coming soon

Western blot validation figures for REC-SerpinB6 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →